Autobio Diagnostics Co Ltd
SSE:603658

Watchlist Manager
Autobio Diagnostics Co Ltd Logo
Autobio Diagnostics Co Ltd
SSE:603658
Watchlist
Price: 41.25 CNY -1.08% Market Closed
Market Cap: 24B CNY
Have any thoughts about
Autobio Diagnostics Co Ltd?
Write Note

Gross Margin
Autobio Diagnostics Co Ltd

64.9%
Current
61%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
64.9%
=
Gross Profit
3B
/
Revenue
4.6B

Gross Margin Across Competitors

Country CN
Market Cap 24B CNY
Gross Margin
65%
Country JP
Market Cap 7T JPY
Gross Margin
86%
Country CH
Market Cap 37.8B CHF
Gross Margin
55%
Country DK
Market Cap 178.8B DKK
Gross Margin
68%
Country US
Market Cap 16.1B USD
Gross Margin
70%
Country KR
Market Cap 10.5T KRW
Gross Margin
15%
Country CN
Market Cap 51.1B CNY
Gross Margin
72%
Country US
Market Cap 6.5B USD
Gross Margin
65%
Country CA
Market Cap 6.4B USD
Gross Margin
61%
Country US
Market Cap 5.7B USD
Gross Margin
47%
Country UK
Market Cap 4.6B GBP
Gross Margin
56%
No Stocks Found

Autobio Diagnostics Co Ltd
Glance View

Market Cap
24B CNY
Industry
Health Care

Autobio Diagnostics Co., Ltd. is a company that has carved a distinctive niche in the biotechnology landscape, particularly within the realm of in-vitro diagnostics (IVD). The company's journey began with a mission to enhance healthcare by providing advanced diagnostic tools that offer precise and timely results. Specializing in the development, production, and distribution of diagnostic reagents and instruments, Autobio has dedicated itself to innovation and quality in medical diagnostics. Its expansive product portfolio covers areas such as immunoassay detection, microbiology, clinical chemistry, and molecular diagnostics, catering to both hospital laboratories and independent labs. The firm prides itself on adopting cutting-edge technology to create solutions that are not only efficient and cost-effective but also align with global health standards. The financial heartbeat of Autobio lies in its strategic approach to generating revenue through diverse streams. With a keen focus on research and development, the company continually innovates its product lines, thereby sustaining a competitive edge in the fast-evolving diagnostics market. Additionally, its revenue model capitalizes heavily on the consumables-market; reagents and test kits are used in routine diagnostics, creating a recurring income source as these products need constant replenishment. By expanding its geographic footprint through partnerships and direct sales channels, Autobio enhances its market reach, strengthening its ability to leverage scale economies. Moreover, the company’s commitment to maintaining strong customer relationships through robust after-sales service and technical support has built a loyal base, further fueling its revenue engine.

Intrinsic Value
75.56 CNY
Undervaluation 45%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
64.9%
=
Gross Profit
3B
/
Revenue
4.6B
What is the Gross Margin of Autobio Diagnostics Co Ltd?

Based on Autobio Diagnostics Co Ltd's most recent financial statements, the company has Gross Margin of 64.9%.